You are here

Article Text

Article menu
Download PDFPDF
Editorial
Will oral antithrombin agents replace warfarin?
  1. P R Sinnaeve,
  2. F J Van de Werf
  1. Department of Cardiology, University of Leuven, Leuven, Belgium
  1. Correspondence to:
    F J Van de Werf MD PhD
    Department of Cardiology, Gasthuisberg University Hospital, Herestraat 49, B-3000 Leuven, Belgium; frans.vandewerfuz.kuleuven.ac.be

Abstract

The new oral direct thrombin inhibitor ximelagatran is at least equivalent to warfarin for stroke prevention in patients with non-valvar atrial fibrillation, and seems to be a promising adjunct to aspirin after acute coronary syndrome

  • ACS, acute coronary syndrome
  • AF, atrial fibrillation
  • DTI, direct thrombin inhibitor
  • ESTEEM, efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage
  • INR, international normalised ratio
  • NSTEMI, non-ST elevated myocardial infarction
  • SPORTIF, stroke prevention using an oral thrombin inhibitor in patients with atrial fibrillation
  • oral antithrombin agents
  • warfarin
  • thrombosis
  • ximelagatran

https://doi.org/10.1136/hrt.2003.030379

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Linked Articles

    • Miscellanea
      WEB TOP 10
      BMJ Publishing Group Ltd and British Cardiovascular Society
      Heart 2004; 90 1210-1210 Published Online First: 14 Sep 2004.
    • Miscellanea
      WEB TOP 10
      BMJ Publishing Group Ltd and British Cardiovascular Society
      Heart 2004; 90 1343-1343 Published Online First: 14 Oct 2004.
    • Miscellanea
      WEB TOP 10
      BMJ Publishing Group Ltd and British Cardiovascular Society
      Heart 2004; 90 1373-1373 Published Online First: 16 Nov 2004.